Printer Friendly
The Free Library
22,710,190 articles and books

Medinet, Two Medical Institutions Jointly Launch Clinical Studies of Gamma-delta T Cell Therapy for Multiple Myeloma.

Tokyo, Japan, Dec 7, 2005 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - Japanese contract research organization (CRO) Medinet has signed a joint research agreement with two medical institutions, the Japanese Red Cross Medical Center and the Shin-Yokohama Medical Clinic.

The three partners will jointly undertake through March 2006 clinical studies of lymphokine-activated killer cell In cell biology, a lymphokine-activated killer cell (also known as a LAK cell) is a white blood cell that has been stimulated to kill tumour cells.[1] If lymphocytes are cultured in the presence of Interleukin 2, it results in the development of effector cells  therapy using gamma-delta T cells T cells
A type of white blood cell produced in the thymus gland. T cells are an important part of the immune system. Infants born with an underdeveloped or absent thymus do not have a normal level of T cells in their blood.
. Specifically, they aim to verify the safety and validity of cell therapy in treating multiple myeloma, a type of blood cancer that develops anemia, renal damage, bone pain and fracture, and hypercalcemia Hypercalcemia Definition

Hypercalcemia is an abnormally high level of calcium in the blood, usually more than 10.5 milligrams per deciliter of blood.

Medinet will provide raw data on the therapy to the institutions while analyzing results obtained from the clinical studies.

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion




Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Dec 9, 2005
Previous Article:Toshiba Develops MEMS-based Cell Manipulation Method.
Next Article:Rohm and Haas Japan Introduces New Rheology Modifier ACULYN 38.

Related Articles
Silicone gel stimulates tumors in mice.
Tea time for T cells.
Old and new drugs may fight myeloma.
Nonsecretory multiple myeloma.
Multiple myeloma in a patient with hoarseness, dysphagia, aspiration, and cervical lymphadenopathy.
Medinet to Support University of Tokyo Hospital's 22nd Century Medical Center Project for Immune Cell Therapy.
Medinet, University of Tokyo Hospital Jointly Undertake Animal Experiments for Immune Cell Therapy.
MEDINET, Yokohama City University, Shin-Yokohama Medical Clinic Jointly Launch Clinical Study of Immune Cell Therapy for Pancreatic Cancer.
Medinet, University of Tokyo, Shin-Yokohama Medical Clinic Jointly Launch Clinical Studies of Activated Self Gamma-delta T Cell Therapy for Non-Small...
Fragile bones in a young male.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters